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strand breaks via the base excision pathway. PARP inhibitors such as
olaparib lead to an accumulation of double-strandDNAbreaks, resulting
in the activation of homologous recombination repair (Ashworth,
2008). Thus, patients with defects in the repair of double-strand DNA
breaks by homologous recombination, including those with BRCA1
and BRCA2 mutations are sensitive to PARP inhibition.
There are different indications for the use of olaparib in advanced
HGSOC. In Europe, olaparib is approved for maintenance treatment in
patients with platinum-sensitive relapsed BRCA-mutated HGSOC with
complete or partial response to their most recent platinum-based che-
motherapy. In this setting, median progression-free survival is 11.2
monthswith olaparibmaintenance therapy versus 4.3monthswith pla-proved to treat patients with platinum-sensitive and platinum–1. Introduction
Ovarian cancer related brain metastases (BM) are uncommon, the re-
ported incidence ranges from 0.49 to 11.54% and they usually arise two
years after diagnosis (Pakneshan et al., 2014). However, rates may be
higher as brain imaging is not routinely performed. The cerebellum is
the most common site for metastatic spread, while leptomeningeal dis-
ease has been reported to only affect 8% of patients with BM.
Leptomeningeal disease is deﬁned as metastatic spread to the cere-
brospinal ﬂuid and the leptomeninges. It usually has debilitating conse-
quences, as it can cause cognitive impairment, increased intracranial
pressure, cranial nerve palsies and radiculopathies. It is diagnosed by ce-
rebrospinal ﬂuid cytology and contrast-enhanced MRI scans. The opti-
mal treatment for affected patients is unknown (Pakneshan et al.,
2014).
Patients with BRCA-mutated high grade serous ovarian cancer
(HGSOC) have higher rates of visceral metastases (lung, spleen and
liver) compared to sporadic cases where the disease is usually limited
to the peritoneum (Gourley et al., 2010). Among patients with HGSOC
the rate of BRCA1/2 germline and somatic mutations is about 22%
(Cancer GenomeAtlas ResearchNetwork, 2011). However, homologous
recombination defects are present in approximate half of HGSOC pa-
tients (Cancer Genome Atlas Research Network, 2011). Poly(ADP-St, London WC1E 6BT, UK.
n).
. This is an open access article undercebo (p b 0.0001) (Ledermann et al., 2014). In the U.S., olaparib is ap-
resistant advanced BRCA-mutated HGSOC who have received ≥3 lines
of chemotherapy, as the median duration of response in these two
groups is 8.2 and 8 months, respectively (Domchek et al., 2016).
To the best of our knowledge, herein we report the ﬁrst case of a pa-
tient with BRCA-mutated HGSOC who received the PARP inhibitor,
olaparib to treat leptomeningeal disease on a compassionate basis.2. Case report
A 61 year old lady commenced olaparib for BRCA2-mutated Interna-
tional Federation of Gynecology and Obstetrics (FIGO) stage IVB HGSOC
with leptomeningeal disease in the absence of extra-cranial recurrence
(Figs. 1 and 2).
She was diagnosed with ovarian cancer six years previously, follow-
ing presentationwith abdominal distension secondary tomalignant as-
cites associated with a serum cancer antigen 125 (CA-125) level of 465
kIU/L. An omental biopsy demonstrated adenocarcinoma inﬁltration
which was positive for cytokeratin 7 (CK7), Wilms tumor gene product
(WT1) and CA-125 on immunohistochemistry. Baseline CT staging sug-
gested FIGO stage IVB disease due to pleural nodules and intrathoracic
lymphadenopathy. She had no priormedical problems aside from stress
incontinence treated by colposupsension. Her daughter had been previ-
ously treated for non-Hodgkin lymphoma but therewas no other signif-
icant family history.
Following 3 cycles of neoadjuvant carboplatin and paclitaxel there
was a radiological and CA-125 response (53 kIU/L) and she underwentthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. MRI brain scans demonstrating response of skull base leptomeningeal disease to olaparib (T1 weighted, post gadolinium contrast, coronal sections): a) Enhancing skull base
leptomeningeal disease pre-olaparib. b) Signiﬁcant decrease in volume and enhancement of skull base leptomeningeal disease after 6 months of olaparib. c) Unchanged signiﬁcant
decrease in volume and enhancement of skull base leptomeningeal disease after 12 months of olaparib.
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phorectomy, tumor debulking and omentectomy). After 3 cycles of
postoperative carboplatin and paclitaxel there was no residual disease
on CT scanning and the CA-125 was 35 kIU/L.
Unfortunately, two years later she developed right hemi-dysesthesia
and a CT head scan demonstrated a solitary left parietal lesion. She
underwent a craniotomy and the resected tumor was CK7 and CA-125
positive carcinoma, thus compatible with the primary disease. A post-
operative MRI head scan did not demonstrate any residual disease and
she underwent radiotherapy to the tumor bed (20 Gy/5 fractions). She
made a good recovery, with only residual paraesthesia in her right
foot. A re-staging scan did not demonstrate any extra-cranial disease
and serum CA-125 was 36 kIU/L. She underwent stereotactic radiosur-
gery (SRS) one year post-craniotomy, as a follow upMRI scan identiﬁed
tumor recurrence within the left parietal resection cavity. The patient
was asymptomatic and imaging studies did not reveal any extra-cranial
disease.
Over the next few months, she developed problems with balance,
right sensorineural hearing impairment and right sided trigeminal
dysesthesia. She also developed numbness of her buttocks and left
foot, in addition to decreased sensation during micturition and defeca-
tion, but she maintained continence. An MRI scan of the brain and
spine demonstrated new leptomeningeal thickening, radiological en-
hancement at the skull base and in the lumbosacral spinal canal (Figs.
1a and 2a). The appearance of the left parietal surgical resection site
was stable. Cerebrospinal ﬂuid (CSF) cytology demonstrated atypical
cells which stained for MNF116 (pan-cytokeratin antibody), consistent
with meningeal inﬁltration. There was no extra-cranial disease on CT
scanning and serum CA-125 had risen to 64 kIU/L.Fig. 2. MRI spine scans demonstrating complete resolution of leptomeningeal disease at
leptomeningeal disease at the L4 vertebral level prior to olaparib. b) Normal appearances a
Normal appearances at the site of the previous spinal leptomeningeal disease after 12 monthsShe commenced treatment with single agent carboplatin but had an
hypersensitivity reaction during cycle four. Subsequently, she was
switched to a carboplatin ‘de-sensitisation’ regimen but experienced
an anaphylactic reaction and treatment was discontinued. At the end
of chemotherapy, her symptoms had improved but she was still trou-
bled by right-sided hearing impairment and right-sided trigeminal
dysesthesia. The CSF cytology was negative, serum CA-125 was
45 kIU/L and radiological restaging revealed stable intracranial disease
and no extracranial recurrence.
However, there was deterioration in her neurological symptoms at
seven months post-carboplatin; at this stage she underwent BRCA test-
ing as it had become publicly-funded for non-mucinous ovarian cancer
patients, and she was found to have a deleterious BRCA 2mutation. Un-
fortunately, she had bilateral trigeminal dysesthesia, she was unable to
open her mouth fully and had difﬁculty both chewing and swallowing.
She had lower back pain and hermobility had deteriorated to the extent
that she required walking aids. On repeat MR imaging, there was pro-
gressive leptomeningeal disease to account for the patient's worsening
neurological symptoms, in the absence of extracranial recurrence on
CT staging. In particular, there was leptomeningeal disease, involving
Meckel's cave bilaterally, the cisternal portions of the trigeminal nerves
bilaterally and right internal auditory meatus, as well as increased
intradural extra-medullary disease within the lumbo-sacral spine on
MR scanning (Figs. 1a and 2a).
She commenced olaparib capsules 400 mg twice daily with symp-
tomatic beneﬁt within two weeks, including complete resolution of
back pain, decreased facial pain, improved swallowing and full mouth
opening. The dose was reduced to 200 mg twice daily by month three
due to severe treatment-related fatigue, which was signiﬁcantlythe L4 vertebral with olaparib treatment (T2 weighted, axial sections). a) Enhancing
t the site of the previous spinal leptomeningeal disease after 6 months of olaparib. c)
of olaparib.
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sation, bladder sensation and balance had all improved but had not fully
resolved. In addition, she was able to walk short distances without
walking aids. However, the right hearing impairment was unchanged.
The clinical response was consistent with MR imaging. Intracranially,
there was a dramatic decrease in leptomeningeal disease at the skull
base (Fig. 1b). Intraspinally, the leptomeningeal disease had decreased
to the point that it was no longer visible on MR imaging (Fig. 2b).
These ﬁndings were associated with a fall in CA-125 from 62 to 37
kIU/L.
Unfortunately, after twelve months of olaparib, surveillance MR
scanning demonstrated a new 2 cm deposit within the right occipital
lobe which was not associated with any symptoms, the serum CA-125
had risen to 66 kIU/L. The left parietal resection cavity was unchanged
and the intracranial leptomeningeal disease remained stable aside
from progressive hypothalamic disease. Furthermore, there was no
recurrence of the intra-spinal or extra-cranial disease. The patient is
now scheduled to undergo SRS and has discontinued olaparib.
3. Discussion
The patient presented had a sustained clinical and radiological
response to olaparib for leptomeningeal metastases related to BRCA2
mutantHGSOC. Based on data frompooled case series, themedian over-
all survival (OS) for patients with ovarian cancer BM is 6.4 months
(Piura and Piura, 2011).
There are several prognostic indices for patients with BM arising
from solid malignancies which take into account various factors, such
as size and number of BM, patients' age, performance status and prima-
ry disease status (Sperduto et al., 2008). Retrospective studies have
demonstrated that the indices can be applied to ovarian cancer patients
(Chenet al., 2005). For patientswith ovarian cancer BM, progressive pri-
mary disease and presence of multiple BM are associated with worse
survival outcomes (Chen et al., 2005). In general, prognostic indices
can help to stratify patients, in order to identify patients who will ben-
eﬁt most from a proactive treatment approach.
Currently, there is no agreed consensus regarding the optimal treat-
ment for HGSOC central nervous system (CNS)metastases (Divine et al.,
2016). Treatment options for parenchymal BM include whole brain ra-
diation therapy (WBRT), surgery or SRS in combination with WBRT
and SRS alone, as well as systemic chemotherapy (Walter et al., 2015).
Retrospective studies suggest thatmultimodal therapy could offer a sur-
vival advantage compared toWBRT alone (Piura and Piura, 2011). How-
ever, treatment options for HGSOC leptomeningeal disease are more
limited and include partial or WBRT and chemotherapy (systemic and
or intrathecal) (Teckie et al., 2013; Yust-Katz et al., 2013). The reported
median OS for patients from diagnosis of HGSOC leptomeningeal
disease is b4 months and the beneﬁt of conventional treatments are
uncertain.
This patient gained signiﬁcant symptomatic beneﬁt from olaparib
with an associated improvement in her quality of life and treatment
was well tolerated following a dose reduction for treatment-related fa-
tigue. In addition, it was possible to avoid WBRT which is associated
with neurocognitive deﬁcits, that can arise within a few months of
treatment (Walter et al., 2015).
In a review of ovarian cancer BMpublished in 2011, b600 caseswere
reported in the literature (Piura and Piura, 2011), Given the paucity of
cases it will not be feasible to conduct a clinical trial of PARP inhibitors
in patients with leptomeningeal disease, thus, highlighting the impor-
tance of sharing case reports in the literature. However, future clinicaltrials could focus on a larger group of patients with BM related to
BRCA mutated breast or HGSOC to assess the use of PARP inhibitors in
this setting.
Consent
Written informed consent was obtained from the patient for publi-
cation of this case report.
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